KOSDAQBiotech & Pharma080720

Union Korea Pharm

₩2,410 0.00%2026-11-18 close
Market Cap
₩192.4B
Turnover
₩0
Volume
0 shares
Shares out.
79.9M
PER
—
PBR
6.2×
EPS
-₩254
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Losses narrowing after restructuring, capital repair still ahead

Restructuring has ended and a new controlling shareholder is in place, but operating losses have run for five straight quarters, so operating breakeven has not yet appeared.

  1. 1

    Sales peaked at KRW 63.2 billion in 2023, then fell to KRW 51.3 billion in 2024 and KRW 36.4 billion in 2025.

  2. 2

    Operating losses were recorded for three straight years from 2023 to 2025, with the 2025 loss widening to KRW 17.2 billion.

  3. 3

    Q3 2026 sales rose to KRW 7.77 billion, up 30.7% from the prior quarter, while the operating loss widened to KRW 3.5 billion.

  4. 4

    Q2 2026 swung to a KRW 2.14 billion net profit attributable to controlling shareholders, while the operating loss in the same quarter was KRW 1.25 billion.

  5. 5

    Restructuring was closed by court decision on August 31, 2026, and the company said its debt ratio has improved to the 40% range.

02

Business structure

Union Korea Pharm is a pharmaceutical manufacturer listed on KOSDAQ in July 2018, producing injectables and solid dosage forms at its Wonju Munmak plant in Gangwon Province. The Wonju plant received GMP (Good Manufacturing Practice) plant approval from the Ministry of Food and Drug Safety in March 2020.

Sales have run mainly through a contract sales organization (CSO) model introduced around 2020 to improve cost efficiency. A 2024 press report noted that revenue grew under the CSO model but rising commission fees kept the company in losses.

Amid weak performance and management strain, the Wonju plant's utilization rate was 29 percent in Q3 2025. On January 5, 2026, Bukwang Pharm was selected as the final acquirer, and it became the largest shareholder after paying KRW 30 billion for new shares on May 27, 2026.

Bukwang Pharm said the purpose was to expand production capacity through control of a manufacturer.

Union Korea Pharm began producing a digestive enzyme product that Bukwang Pharm had previously outsourced, shipping it for the first time in June 2026, and two thyroid and endocrine OTC products were scheduled to ship from September 2026.

A 2024 press report said most of the product lineup consists of generics, which leaves the business exposed to price competition and drug pricing regulation. The model is shifting from self-directed sales toward a manufacturing role that also takes contract production volume from the group.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩7.1B-₩9.9B−139.0%
2025Q4₩6.5B-₩2.6B−40.9%
2026Q1₩5.9B-₩1.6B−26.5%
2026Q2₩5.9B-₩1.3B−21.1%
2026Q3₩7.8B-₩3.5B−45.0%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩61.3B₩1.3B-₩900M2.1%−1.9%131.5%
2023₩63.2B-₩5.2B-₩18.2B−8.3%−59.9%211.4%
2024₩51.3B-₩13.5B-₩20.9B−26.2%−253.0%808.0%
2025₩36.4B-₩17.2B-₩30.8B−47.4%—−300.1%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-16

04

Earnings analysis

Annual sales were KRW 61.3 billion in 2022 and KRW 63.2 billion in 2023, up 3.1 percent, then fell to KRW 51.3 billion in 2024, down 18.8 percent, and KRW 36.4 billion in 2025, down 29.1 percent. Within 2022 to 2025, 2023 was the largest year for sales and 2025 the smallest.

A 2024 press report put 2021 sales at about KRW 48.3 billion, and the 2022 to 2023 growth is attributed to expansion under the CSO model. Operating profit of KRW 1.27 billion in 2022 turned into an operating loss of KRW 5.23 billion in 2023, then KRW 13.5 billion in 2024 and KRW 17.2 billion in 2025.

The operating margin moved from 2.1 percent in 2022 to -8.3 percent in 2023, -26.2 percent in 2024 and -47.4 percent in 2025. fnguide reported that for the first nine months of 2025, sales fell 36.9 percent year on year and the operating loss rose 156.7 percent, citing lower product and merchandise sales and a shrinking CMO business.

Net losses attributable to controlling shareholders widened to KRW 18.2 billion in 2023, KRW 20.9 billion in 2024 and KRW 30.8 billion in 2025, and the net loss including non-controlling interests was reported at the same amounts.

Operating cash flow was -KRW 5.06 billion in 2022, KRW 1.36 billion in 2023, KRW 415 million in 2024 and -KRW 1.13 billion in 2025.

The filed year-end 2025 total equity of KRW 22.9 billion appears alongside a debt ratio of -300.1 percent, which points to negative equity, and fnguide classified year-end 2025 equity as negative KRW 22.6 billion with full capital impairment.

On a quarterly basis, sales were KRW 7.13 billion with an operating loss of KRW 9.91 billion in Q3 2025, and Q1 2026 marked the low point at KRW 5.9 billion in sales and a KRW 1.57 billion operating loss.

Sales were KRW 5.94 billion in Q2 2026 with a KRW 1.25 billion operating loss, then rose to KRW 7.77 billion in Q3 2026, up 30.7 percent from the prior quarter and 9.0 percent from a year earlier.

However, the Q3 2026 operating loss widened to KRW 3.5 billion and the net loss attributable to controlling shareholders was KRW 6.98 billion. The Q2 2026 swing to a net profit attributable to controlling shareholders, while operations stayed in loss, may reflect non-operating or one-off items.

The four quarters from Q4 2025 to Q3 2026 total a net loss attributable to controlling shareholders of KRW 20.3 billion.

05

Industry analysis

Demand from downstream markets is strongly shaped by domestic drug pricing policy and prescribing conditions. fnguide summarized that tighter drug pricing and kickback rules led to lower sales and weaker profitability.

A generic-heavy product mix is exposed to price competition, and together with commission fees under the CSO model, this appears to have squeezed margins.

On the production side, contract manufacturing demand has emerged as a new source of volume, as Bukwang Pharm began moving products it had outsourced because of limited capacity into this company's plant.

On an industry aggregate basis, fnguide's KOSDAQ pharmaceuticals comparison shows positive operating profit, so the company's operating loss sits outside the sector average.

Compared with Samsung Biologics, which expands on large-scale facilities, this company runs a mid-sized production base whose utilization was 29 percent in Q3 2025.

The cycle position can be described as the early stage of a production efficiency recovery, but the operating margin is still negative and the recovery has not yet appeared in the numbers. Limits on self-directed sales growth may persist while generic price competition and drug pricing regulation continue.

06

Outlook

The company, together with its new controlling shareholder, has said it will pursue sales growth and a swing to profit by strengthening operating and manufacturing synergies.

The new controlling shareholder has said its own results should expand in scale and improve in profitability once this company's results are reflected. Restructuring plan approval came on May 12, 2026, and the restructuring proceedings closed on August 31, 2026.

The company said past trade payables, borrowings and bond-with-warrant obligations were all repaid, and that the debt ratio improved to the 40 percent range, with a substantive ratio of about 15 percent.

That figure is based on a different date than the year-end 2025 filed debt ratio and should be read with that in mind. The exchange decided on delisting in April 2026, and the company applied for a provisional injunction the same month, but an October 2026 report still described it as a KOSDAQ-listed company.

At a July 2026 extraordinary shareholders' meeting, all seven existing directors resigned and a new board was elected, including a new chief executive.

A 3-to-1 share consolidation covering 365,003 common shares issued in a debt-to-equity conversion was set with a record date of November 6, 2026, and listing of the new shares is scheduled for November 30, 2026.

The next confirmation points are the annual sales and operating results in the 2026 annual report and whether the operating loss narrows in Q1 2027.

07

Valuation

PER
—
PBR
6.2×
ROE
-186.4%
EPS
-₩254
BPS
₩391
Dividend per share
₩0

Because the net loss attributable to controlling shareholders has continued across the last four quarters, the price-to-earnings ratio cannot be calculated. With earnings unable to explain the share price, valuation is usually read through assets and dividends.

The price-to-book ratio tends to look high when book equity is negative, so the share price is hard to interpret against asset value. The point at which capital impairment is resolved is the variable that would change how the price-to-book ratio should be read. The dividend yield is below the industry average.

In fnguide's industry comparison, the KOSDAQ pharmaceuticals group shows positive operating profit, so the gap between this company's profit structure and the sector average is wide.

The new share listing scheduled for November 30, 2026 will change the number of shares outstanding, which alters the basis for per-share metrics in time-series comparisons. Because there is no earnings base to anchor a historical multiple band, the current position is hard to explain using multiples alone.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-16

08

Bull factors

Early signs of a profit swing

Net profit attributable to controlling shareholders swung to a KRW 2.14 billion profit in Q2 2026. Sales rose for two straight quarters from the Q1 2026 low to KRW 7.77 billion in Q3 2026.

The operating loss also narrowed from KRW 9.91 billion in Q3 2025 to KRW 1.25 billion in Q2 2026, which supports the case for improvement.

Reduced financial uncertainty

Restructuring proceedings closed by court decision on August 31, 2026, and most restructuring debt has been repaid. The company said its debt ratio improved to the 40 percent range and that the substantive ratio is about 15 percent. If the process of moving out of capital impairment continues, the balance-sheet burden should ease.

Group contract volume and plant utilization

The contract product digestive enzyme was first shipped in June 2026, and two thyroid and endocrine OTC products were reported to be scheduled for shipment from September 2026. Plant utilization stood at 29 percent in Q3 2025, so rising contract volume could raise how much of the production base is used.

09

Bear factors

Operating losses persist

Operating losses were recorded for three straight years from 2023 to 2025, and the Q3 2026 operating loss widened to KRW 3.5 billion from the prior quarter. The four quarters from Q4 2025 to Q3 2026 total a net loss attributable to controlling shareholders of KRW 20.3 billion.

The operating margin fell to -47.4 percent in 2025, and the quarterly figures do not yet show an operating breakeven.

Weakening sales base

Sales peaked at KRW 63.2 billion in 2023, then declined for two straight years to KRW 36.4 billion in 2025. fnguide put first-nine-month 2025 sales down 36.9 percent year on year. Tighter drug pricing and kickback rules are adding pressure on both sales and profitability.

Capital and listing risk

The year-end 2025 debt ratio was reported as -300.1 percent, and fnguide classified equity as fully impaired. The exchange decided on delisting in April 2026, and the company filed for a provisional injunction.

A net loss attributable to controlling shareholders of KRW 6.98 billion in Q3 2026 means the pace of capital recovery remains uncertain.

10

Risk factors

Financial and capital risk

The year-end 2025 total equity of KRW 22.9 billion alongside a debt ratio of -300.1 percent points to capital impairment. The 40 percent and about 15 percent debt ratios that the company cited come from a different date than the year-end 2025 filing.

Operating liabilities such as trade payables and returns provisions remain after restructuring, and the timing of capital recovery is not yet visible in filings.

Listing and governance risk

The exchange decided on delisting in April 2026, and the company's provisional injunction application paused that process for a period. An October 2026 report still described it as a KOSDAQ-listed company.

All seven existing directors resigned at a July 2026 extraordinary shareholders' meeting, and the new management team inherits the execution agenda.

Business execution risk

A large share of the product mix is generic, which leaves sales exposed to price cuts and kickback rules. Production volume increasingly depends on contract work from the group, so if that volume does not grow as expected, utilization gains could be delayed.

Product-level revenue shares are difficult to verify from the sources used here, so detailed changes in the business mix will be visible only in periodic filings.

11

What to watch next

  1. November 30, 2026

    Scheduled listing date for new shares following the 3-to-1 consolidation of shares issued in the debt-to-equity conversion. The change in shares outstanding will alter the basis for per-share metrics in later comparisons.

  2. End of March 2027

    Deadline for the 2026 annual report. Full-year 2026 sales, operating results and total equity, including Q4 2026, will be fixed in the filing, which is the basis for judging whether capital impairment is resolved.

  3. May 15, 2027

    Statutory deadline for the Q1 2027 quarterly report. This is the point to check whether the operating loss, which widened to KRW 3.5 billion in Q3 2026, starts to narrow and whether contract volume shows up in sales.

12

Overall view

Union Korea Pharm has reduced its financial uncertainty through the 2026 change of control to a new shareholder and the close of restructuring. On reported figures, sales have fallen for two straight years since the 2023 peak, and operating losses have run for three straight years from 2023.

The 2026 quarterly pattern shows positive signs, with sales rising after the Q1 low and a Q2 swing to a net profit attributable to controlling shareholders.

On the other side, the Q3 2026 operating loss widened to KRW 3.5 billion, and the four quarters through Q3 2026 total a net loss attributable to controlling shareholders of KRW 20.3 billion. The negative equity indicated at year-end 2025 and the progress of the listing process remain balance-sheet burdens.

Contract volume and financial normalization on one side, and operating losses and falling sales on the other, should be weighed equally. The next confirmation points are full-year operating results in the 2026 annual report and whether the operating loss narrows in Q1 2027.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. thebionews.net
  2. comp.fnguide.com
  3. huffingtonpost.kr
  4. huffingtonpost.kr
  5. bloter.net
  6. pharm21.com
  7. newstomato.com
  8. huffingtonpost.kr
  9. ibtomato.com
  10. news.nate.com
  11. m.news.nate.com
  12. news.nate.com
  13. ket.kr
  14. m.yakup.com
  15. specialtimes.co.kr
  16. kr.investing.com
  17. newsis.com
  18. fnnews.com

Report written 2026-11-16 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis